Pelthos Therapeutics Inc Com (New) (PTHS:NYSEMKT) closed at $18.70 on October 21, 2026, down 8.78% on the day. The stock trades 50.1% below its 52-week high of $37.50 and 2.8% above its 52-week low of $18.19. Over the past year, it lost 43.4%. Pelthos Therapeutics Inc Com (New) is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, PTHS closed higher on 116 days (46%). Its best day was April 6, 2026 (+19.51%) and its worst was November 21, 2025 (-12.41%). The stock moved 10% or more in a single session 11 times. It opened at least 5% above the previous day's high 1 time.
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Find more stocks like PTHS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.